Fertility and Sterility
Volume 93, Issue 6 , Pages 1997-2003 , April 2010

Levonorgestrel effects on serum androgens, sex hormone–binding globulin levels, hair shaft diameter, and sexual function

  • George Kovalevsky, M.D.

      Affiliations

    • Reproductive Associates of Delaware, Newark, Delaware
    • Corresponding Author InformationReprint requests: George A. Kovalevsky, M.D., 4735 Ogletown-Stanton Road, MAP 2, Suite 3217, Newark, Delaware 19713 (FAX: 302-623-4241).
    • ,
  • Susan A. Ballagh, M.D.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
    • ,
  • Frank Z. Stanczyk, Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California
    • ,
  • Jennifer Lee, B.S.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
    • ,
  • Joann Cooper, B.S.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
    • ,
  • David F. Archer, M.D.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia

Received 13 August 2008 ,Revised 29 October 2008 ,Accepted 18 December 2008.

References 

  1. Peterson HB, Curtis KM. Clinical practice. Long-acting methods of contraception. N Engl J Med. 2005;353:2169–2175
  2. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf. 2003;26:303–335
  3. Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab. 2006;91:3189–3198
  4. Li R, Luo X, Archer DF, Chegini N. Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine. J Reprod Immunol. 2007;73:118–129
  5. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75:6–11
  6. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod. 2006;21:295–302
  7. Nilsson B, von Schoultz B. Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. Gynecol Obstet Invest. 1989;27:151–154
  8. Darney PD. The androgenicity of progestins. Am J Med. 1995;98:104S–110S
  9. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertil Steril. 2001;76:461–468
  10. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999;60:255–262
  11. Paulson RJ, Serafini PC, Catalino JA, Lobo RA. Measurements of 3 alpha,17 beta-androstanediol glucuronide in serum and urine and the correlation with skin 5 alpha-reductase activity. Fertil Steril. 1986;46:222–226
  12. Horton R, Hawks D, Lobo R. 3 alpha, 17 beta-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism. J Clin Invest. 1982;69:1203–1206
  13. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab. 1989;68:966–970
  14. Barth JH. Semi-quantitative measurements of body hair in hirsute women compare well with direct diameter measurements of hair shafts. Acta Derm Venereol. 1997;77:317–318
  15. Heiner JS, Greendale GA, Kawakami AK, Lapolt PS, Fisher M, Young D, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab. 1995;80:3412–3418
  16. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:89–94
  17. Lunde O, Grottum P. Body hair growth in women: normal or hirsute. Am J Phys Anthropol. 1984;64:307–313
  18. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000;85:2913–2921
  19. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol (Oxf). 1991;35:5–10
  20. Sagsoz N, Kamaci M, Orbak Z. Body hair scores and total hair diameters in healthy women in the Kirikkale Region of Turkey. Yonsei Med J. 2004;45:483–491
  21. Aisien AO. Contraception with levonorgestrel subdermal implants (Norplant) in Benin-City, Nigeria: a 12-year review. Afr J Reprod Health. 2007;11:90–97
  22. Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception. 2002;65:63–74
  23. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58
  24. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002;77:660–665
  25. Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum Reprod. 1998;13:3371–3378
  26. Croxatto HB, Diaz S, Robertson DN, Pavez M. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. Contraception. 1983;27:281–288
  27. Diaz S, Croxatto HB, Pavez M. Clinical chemistry in women treated with six levonorgestrel covered rods or with a copper IUD. Contraception. 1985;31:321–330
  28. Alvarez F, Brache V, Faundes A, Tejada AS, Thevenin F. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses. Contraception. 1996;54:275–279
  29. Brache V, Alvarez-Sanchez F, Faundes A, Tejada AS, Cochon L. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants. Contraception. 1990;41:169–177
  30. Goebelsmann U, Bernstein G, Gale J, Kletzky O, Nakamura R, Coulson A, et al. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In:  IH L,  R C editor. Vasectomy: Immunologic and Pathophysiologic Effects in Animals and Man. New York: Academic Press; 1979;p. 165–175
  31. Goebelsmann U, Arce JJ, Thorneycroft IH, Mishell DR. Serum testosterone concentrations in women throughout the menstrual cycle and following HCG administration. Am J Obstet Gynecol. 1974;119:445–452
  32. Goebelsmann U, Horton R, Mestman JH, Arce JJ, Nagata Y, Nakamura RM, et al. Male pseudohermaphroditism due to testicular 17-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1973;36:867–879
  33. Serafini P, Ablan F, Lobo RA. 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab. 1985;60:349–355
  34. Stanczyk FZ, Hiroi M, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. Contraception. 1975;12:279–298
  35. Narang R, Rao J, Savjani G, Peterson J, Gentzschein E, Stanczyk F. Radioimmunoassay kit for the quantitative measurement of androstanediol glucuronide in unextracted serum. In: 17th National Meeting of the Clinical Ligand Assay Society. Chicago, 1991:Poster no. 12.
  36. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801–810
  37. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672
  38. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11:1065–1071
  39. Falsetti L, Gambera A. Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Fertil Steril. 1999;72:41–46
  40. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol. 1999;141:361–367
  41. Taylor JF, Rosen RC, Leiblum SR. Self-report assessment of female sexual function: psychometric evaluation of the Brief Index of Sexual Functioning for Women. Arch Sex Behav. 1994;23:627–643
  42. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40
  43. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):51–55
  44. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411–417
  45. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46:917–923
  46. Olsson SE, Odlind V, Johansson E. Androgen levels in women using Norplant implants. Contraception. 1986;34:157–167
  47. Alvarez F, Brache V, Tejada AS, Faundes A. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use. Contraception. 1986;33:111–119
  48. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87:3562–3572
  49. Bowles SM, Mills RJ. Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives. Ann Clin Biochem. 1981;18:226–231
  50. Meston CM, Derogatis LR. Validated instruments for assessing female sexual function. J Sex Marital Ther. 2002;28(Suppl 1):155–164
  51. Mazer NA, Leiblum SR, Rosen RC. The brief index of sexual functioning for women (BISF-W): a new scoring algorithm and comparison of normative and surgically menopausal populations. Menopause. 2000;7:350–363

 G.K. has nothing to disclose. S.A.B. has nothing to disclose. F.Z.S. has nothing to disclose. J.L. has nothing to disclose. J.C. has nothing to disclose. D.F.A. has consulted for Abbott Laboratories, Agile Therapeutics, Bayer Healthcare, Berlex, ConCert Pharmaceutical, Novo Nordisk, Radius, Schering Plough, Warner Chilcott, and Wyeth Laboratories; received research support from Bayer, Duramed, Organon-Schering Plough, Solvay, Warner Chilcott, and Wyeth; and received lecture fees from Novo Nordisk, Organon-Schering Plough, Solvay, Upsher-Smith, and Wyeth.

 This study was supported by National Institute of Child Health and Human Development grant no. R01 HD43175-01.

PII: S0015-0282(08)04798-5

doi: 10.1016/j.fertnstert.2008.12.095

Fertility and Sterility
Volume 93, Issue 6 , Pages 1997-2003 , April 2010

Article Tools

* Image Usage & Resolution